Liquid biopsy is a new technique that makes it easier to identify and monitor lung cancer without surgery. In India, this ...

UChicago researchers have developed a new blood test that uses RNA modifications to detect early-stage colorectal cancer with ...

While the liquid biopsy technology continues to evolve for lung cancer management, researchers are working toward further ...

NeoGenomics launched the NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test, expanding the company’s ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ...

Q2 2025 Management View Helmy Eltoukhy, Co-CEO, stated that "Q2 marked another exceptional quarter for Guardant. We continue to build momentum across oncology, biopharma and screening business lines, ...

Fort Myers-based NeoGenomics reported mixed results for the second quarter. Revenue grew 10% over the year, but the net loss ...

Liquid biopsy technologies are maturing at a rapid pace. They are already being used as a precision medicine tool, helping clinicians match a patient’s cancer to targeted therapies.

Guardant Health raised its FY2025 sales guidance from $880.00 million-$890.00 million to $915.00 million-$925.00 million.

The research team led by Senior Researchers Yoonhee Lee from the Division of Biomedical Technology and Gyogwon Koo from the ...

Liquid biopsy is a noninvasive diagnostic tool that evaluates biomarkers in the blood and other body fluids. "Noninvasive" means that the sample for the liquid biopsy can be obtained with just a ...

Precede Biosciences’ liquid biopsy platform yields insight into the genes and pathways in diseased tissue. Based on Dana-Farber Cancer Institute research, the startup aims to support biopharma ...